Inhibrx Biosciences clinical trials we track

Check company identity source

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)NCT06295731INBRX-106, PembrolizumabRecruiting2029-12Estimated

Phase 2 1 trial

TrialDrugs studiedStatusPrimary completion
Study of INBRX-109 in Conventional ChondrosarcomaNCT04950075INBRX-109Active not recruiting2025-09-30Actual

Phase 1 / 2 1 trial

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Phase 2: Objective Response Rate (ORR) Description: ORR is defined as the proportion of patients with a complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Time frame: up to 6 months Measure: Phase 3: Progression-Free Survival (PFS) Description: PFS is defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST v 1.1, or death from any cause (whichever occurs first). Time frame: From randomization to first occurrence of progressive disease (PD) or death (up to 4 years) Measure: Phase 3: Overall Survival (OS) Description: OS is the time from randomization to death due to any cause Time frame: From randomization until death from any cause (up to 4 years). After: Measure: Phase 2: Objective Response Rate by investigator (ORRinv) Description: defined as the proportion of patients with complete response (CR) or partial response (PR) on 2 consecutive occasions ≥4 weeks apart, as determined by the Investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Time frame: From randomization to progressive disease (PD) or death (up to 1 year) Measure: Phase 3: Progression-Free Survival by Investigator (PFSinv) Description: defined as the time from randomization to first occurrence of PD, as determined by the Investigator according to RECIST 1.1, or death from any cause (whichever occurs first). Time frame: From randomization to PD or death (up to 4 years) Measure: Phase 3: Overall Survival (OS) Description: defined as the time from randomization to death from any cause. Time frame: From randomization until death from any cause (up to 4 years).

Planned enrollment increased by 40 participants

Before: 410 participants (planned). After: 450 participants (planned).

Primary completion date changed

Before: May 2029. After: Dec 2029.

Recruitment status changed

Before: Active not recruiting. After: Recruiting.

Check registry source
Study of INBRX-109 in Conventional Chondrosarcoma

NCT04950075 · Inhibrx Biosciences, Inc

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 201 participants (planned). After: 206 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2025. After: 30 Sep 2025.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source